Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839431 | 0.74 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNACYP1A2CYP2C19 | |
| SCHEMBL355054 | 0.73 | ALDH1A1 (0.50) | ALDH1A1MAPTTSHRLMNAKMT2A | |
| SCHEMBL14839413 | 0.72 | ALDH1A1 (0.40) | ALDH1A1LMNACYP1A2CYP2C19RAB9A | |
| SCHEMBL14839422 | 0.71 | ALDH1A1 (0.41) | ALDH1A1LMNACYP1A2CYP2C19RAB9A | |
| SCHEMBL15910932 | 0.70 | ALDH1A1 (0.40) | ALDH1A1MAPTTSHRLMNACYP1A2 | |
| SCHEMBL29407430 | 0.69 | MAOA (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1557876 | 0.69 | MAOA (0.36) | ALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5733672 | 0.68 | FDPS (0.46) | ALDH1A1MAPTTSHRLMNAKMT2A | |
| SCHEMBL29501850 | 0.66 | RAB9A (0.47) | ALDH1A1MAPTTSHRKMT2ARAB9A | |
| SCHEMBL28403065 | 0.66 | RAB9A (0.47) | ALDH1A1MAPTTSHRKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2762479-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| CN-103030635-A | Biaryl heterocycle-substituted oxazolidinone antibacterial drug | KBP BIOSCIENCES CO LTD | 2013-04-10 | — | — | CN | disclosed |
| WO-2013044845-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | 山东轩竹医药科技有限公司 (CN) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | OXA1L, CYP2C19, CBR3 | ALDH1A1 721/4885MAPT 4672/4885USP2 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.